Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension

Completed · Phase 3

Conditions studied: Hypertension

In brief

The purpose of this study is to assess the potential of using valsartan/HCTZ as initial therapy in patients with severe hypertension compared to valsartan alone as initial therapy, and to determine whether a greater proportion of patients achieve blood pressure control with the combination compared to the monotherapy without producing an unacceptable adverse event profile.

Key facts

Study ID

NCT00273299

Run by

Novartis

People needed

607

Starts

2005-11-01

Expected to finish

2006-07-01

Last updated by the study team

2011-11-08

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed severe hypertension

You may not qualify if…

• Inability to discontinue all prior antihypertensive medications
• Heart failure of any kind
• History of stroke, transient ischemic attack, myocardial infarction, chest pain, abnormal heart rhythm Liver, kidney, or pancreas disease
• Diabetes with poor glucose control
• Allergy to certain medications used to treat high blood pressure
• Other protocol-defined exclusion criteria may apply.

Where it is running

• Novartis Pharmaceuticals — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.